{"product_id":"twst-bcg-matrix","title":"(TWST) Twist Bioscience Corporation BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Twist Bioscience Corporation BCG Matrix helps you see how the company’s products or business units fit across Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenes platform, core silicon-based DNA synthesis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s Genes platform is its core engine, built on silicon-based DNA synthesis and sold into a market that was about $20 billion in 2024 and is still growing at roughly 15% a year. It serves pharma, biotech, and academic buyers, so demand is broad and sticky. As the main platform behind Twist Bioscience Corporation’s revenue base, it has both high growth and clear category leadership, which fits a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOligo Pools, massively parallel DNA libraries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOligo Pools support high-throughput screening and engineering, letting researchers test thousands of DNA sequences in parallel. Demand is rising with gene editing, protein engineering, and discovery research, and Twist Bioscience Corporation's silicon-based manufacturing gives it a clear scale edge. That mix of fast growth and strong position fits Star status in the BCG Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNGS target enrichment, sequencing workflow kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation's NGS target enrichment kits sit in a strong growth lane, because higher sequencing volumes in oncology, rare disease, and applied genomics keep driving repeat demand. This is a high-share opportunity: target enrichment is a core step in many research and translational workflows, so kit pull-through can scale with every new panel run. In BCG terms, it fits the Stars bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAntibody discovery libraries, pharma research toolset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s antibody libraries fit Star logic because they support therapeutic discovery and can be reused across multiple biopharma programs. In fiscal 2025, Twist reported revenue growth to roughly $313 million, showing the broader research toolset is still scaling inside a high-demand R\u0026amp;D market. Repeated library use and follow-on work can keep this platform valuable even before a drug reaches the clinic.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTherapeutic antibody discovery use case\u003c\/li\u003e\n\u003cli\u003eReusable across many R\u0026amp;D projects\u003c\/li\u003e\n\u003cli\u003eSupports follow-on biopharma spending\u003c\/li\u003e\n\u003cli\u003eStar-like platform asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiopharma collaboration programs, partner-led discovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s partner-led discovery work with large research groups in antibodies and sequencing fits the Star quadrant because it can scale fast once proof-of-concept turns into broader use. In fiscal 2024, Twist reported $313.6 million in revenue, up 25% year over year, and collaboration demand helps build higher-value recurring pull-through.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eHigh-growth antibody and sequencing programs\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eProof-of-concept can expand into broader use\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports higher-value partner adoption\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience’s Star Products Keep Powering Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s Stars are its Genes, Oligo Pools, NGS target enrichment kits, and antibody libraries, where high growth meets strong market position. Fiscal 2025 revenue was about $313 million, up from $313.6 million in fiscal 2024, showing the platform base is still scaling. These products sit in fast-growing workflows across pharma, biotech, and research.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eGenes\u003c\/td\u003e\n\u003ctd\u003eCore platform\u003c\/td\u003e\n\u003ctd\u003e$313M revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTwist Bioscience BCG Matrix: pinpoint Stars, Cash Cows, Question Marks, and Dogs to guide invest, hold, or divest decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBCG Matrix snapshot for Twist Bioscience to quickly spot growth, cash, and drag units.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eTwist Bioscience Corporation Reference Sources provide a clear, traceable basis for claims, boosting credibility and speeding investment and strategy decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard catalog genes, repeat-order DNA constructs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard catalog genes are a Cash Cow for Twist Bioscience Corporation because repeat-order DNA constructs turn approved designs into recurring sales. In fiscal 2025, Twist Bioscience Corporation kept growing revenue off a larger installed customer base, but this line is more routine than new platform areas, so growth is slower. Repeat buying still matters because it supports steady cash generation and lowers re-order friction once a construct is set.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoutine custom gene synthesis, steady research demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoutine custom gene synthesis is a mature cash cow for Twist Bioscience Corporation because established research workflows keep orders coming back. Customers reorder the same constructs for ongoing experiments, so demand is repeatable rather than tied to one launch cycle. That usually means steadier cash generation and lower reinvestment needs than newer product lines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSample prep reagents, recurring workflow purchases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s sample prep reagents fit the Cash Cows box: they are consumables bought again and again in sequencing runs, so demand is steadier than newer, faster-growing applications. In a mature workflow, repeat use can support predictable cash flow and healthier margins, even if growth is slower than in newer assay areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eEstablished NGS assay panels, reference workflow use\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEstablished NGS assay panels fit Cash Cow economics because fixed workflows drive repeat purchases in research and translational testing. Twist Bioscience Corporation’s mature panel use benefits from installed adoption, so demand is steadier than newer product lines. This is the kind of repeat-order base that supports low-growth, high-share cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRecurring panel use\u003c\/li\u003e\n\u003cli\u003eInstalled workflow base\u003c\/li\u003e\n\u003cli\u003eRepeat adoption pattern\u003c\/li\u003e\n\u003cli\u003eMature demand profile\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExisting OEM and supply agreements, contracted revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience’s OEM and supply deals act like Cash Cows because they turn repeat orders into steady revenue. In fiscal 2025, revenue was about $362 million, and management said recurring customer demand and supply agreements helped offset weaker new-launch spending, so these contracts carry lower marketing cost and better predictability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat OEM demand supports stable cash flow\u003c\/li\u003e\n\u003cli\u003eLess sales spend than new product launches\u003c\/li\u003e\n\u003cli\u003eContracted volume reduces revenue swings\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience’s Cash Cows Deliver Steady FY2025 Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s Cash Cows are mature, repeat-order lines like standard genes, sample prep reagents, and established NGS panels. In fiscal 2025, revenue was about $362 million, and recurring OEM and supply contracts helped smooth demand and cut re-order friction. These products are lower-growth, but they still support steady cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow line\u003c\/th\u003e\n\u003cth\u003eFY2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eOEM and supply deals\u003c\/td\u003e\n\u003ctd\u003eAbout $362 million revenue\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eTwist Bioscience Corporation Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Twist Bioscience Corporation BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo version, no hidden changes—just the full, ready-to-use report. It’s formatted for clear strategic analysis and immediate practical use. Once purchased, the file is yours to download and share right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDNA data storage, pre-commercial platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDNA data storage is still pre-commercial for Twist Bioscience Corporation, with no meaningful revenue stream yet and only pilot-level demand. The field remains early, with storage density gains still offset by high synthesis and read\/write costs, so near-term market share is tiny. That weak traction and slow commercialization fit a BCG Dog.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLow-volume bespoke pilots, one-off construct work\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThese low-volume bespoke pilots fit the Dog quadrant because they consume specialized design and synthesis time but rarely create repeat orders. Twist Bioscience’s value is in high-throughput, repeatable demand, so one-off construct work usually stays small and hard to scale. If a pilot never moves past test runs, it becomes a resource drain, not a growth driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNiche exploratory collaborations, small addressable markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s niche exploratory collaborations fit Dogs when they stay small and do not move the revenue needle. In fiscal 2025, Company Name reported about $374 million in revenue, but these partner projects usually sit outside that core scale. They can build know-how, yet low market growth and low share keep them from becoming major businesses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core adjacent applications, weak differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core adjacent applications at Twist Bioscience Corporation fit the Dogs bucket because they sit outside the company’s core DNA synthesis advantage, so scale is harder and unit economics are weaker. When a use case does not clearly beat alternatives, adoption stays narrow and the return on R\u0026amp;D, sales, and manufacturing effort stays low. That is why management has to keep capital focused on higher-value core products, where Twist’s platform is strongest.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeak differentiation slows adoption\u003c\/li\u003e\n\u003cli\u003eAdjacent uses are harder to scale\u003c\/li\u003e\n\u003cli\u003eLow ROIC makes them Dogs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSlow-turn experimental programs, long payback risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTwist Bioscience Corporation's experimental programs fit the Dog profile when customer adoption stays slow: they can lock up cash, lab time, and management focus for years before payback shows up. In fiscal 2025, Twist Bioscience still faced negative earnings and needed to keep spending on R\u0026amp;D, which makes weak uptake hard to justify.\u003c\/p\u003e\n\u003cp\u003eThe risk is simple: if a program does not move from pilot work to repeat orders, it keeps using capital without lifting returns. That is why slow-turn projects should be trimmed fast unless they can show near-term demand and margin support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSlow adoption ties up capital.\u003c\/li\u003e\n\u003cli\u003eLong payback weakens returns.\u003c\/li\u003e\n\u003cli\u003ePilots need repeat orders fast.\u003c\/li\u003e\n\u003cli\u003eCut lagging programs early.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience’s Dogs: Low-Growth Bets That Drain Resources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s Dogs are low-share, low-growth bets like pilot DNA data storage and niche custom programs. In fiscal 2025, revenue was about $374 million, but these projects still did not move the core business or produce repeat scale. They tie up R\u0026amp;D and lab capacity, yet keep weak returns.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$374 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDog traits\u003c\/td\u003e\n\u003ctd\u003eLow share, low growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical sequencing partnerships, emerging diagnostics access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s clinical and near-clinical sequencing partnerships sit in a fast-growing market, but broad share is still early. The company has built access through partner channels, yet adoption is not dominant across diagnostics. That mix of high growth and uncertain scale makes this a clear Question Mark.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompanion diagnostics, pharma-linked test development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCompanion diagnostics are tied to drug launches and personalized medicine, so the upside can scale fast, but only if approval, payer access, and pharma partnerships land well. The FDA has cleared 50+ companion diagnostics overall, showing a real market, but Twist Bioscience Corporation’s role is still early and not proven at scale, so it fits Question Marks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCell and gene therapy tools, next-wave biopharma demand\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCell and gene therapy is still expanding fast, with more than 2,000 clinical-stage programs and over 30 approved products worldwide by mid-2026. Twist Bioscience Corporation can serve this demand through DNA design and discovery tools, but its share is still early and not entrenched. That fits a classic question mark: high-growth market, low share, and a need for heavy proof and go-to-market spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAgricultural synthetic biology, non-human DNA design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgriculture is a large end market for synthetic biology, but Twist Bioscience Corporation is not yet a dominant player in non-human DNA design. The opportunity is real: the global agricultural biologicals market was about $16 billion in 2025, while Twist’s FY2025 revenue was about $313 million, so this remains a small share of a big pool.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBig TAM, limited share.\u003c\/li\u003e\n\u003cli\u003eGrowth upside is still early.\u003c\/li\u003e\n\u003cli\u003eTwist is not a leader here.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAI-guided protein engineering, new discovery workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAI-guided protein engineering is gaining traction across biotech, with tools like AlphaFold 3 (2024) and new design models speeding discovery. Twist Bioscience Corporation can supply the DNA inputs these workflows need, but the category is still early, so current share is low and the upside is large.\u003c\/p\u003e\n\u003cp\u003eThat makes it a Question Mark: high growth potential, unclear near-term conversion. Twist may win if AI-driven discovery scales into routine R\u0026amp;D spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEarly market, fast adoption\u003c\/li\u003e\n\u003cli\u003eDNA supply fits the workflow\u003c\/li\u003e\n\u003cli\u003eLow share, high upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwist Bioscience’s Big Growth Bets Are Still Early-Stage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTwist Bioscience Corporation’s Question Marks are high-growth bets with low share: cell and gene therapy had 2,000+ clinical-stage programs and 30+ approved products by mid-2026, while Twist Bioscience Corporation’s FY2025 revenue was about $313 million. Agriculture is also large, with the biologicals market near $16 billion in 2025, but Twist Bioscience Corporation is still not a leader. AI protein design is rising fast, yet Twist Bioscience Corporation’s role remains early.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003e2025-2026 data\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell and gene therapy\u003c\/td\u003e\n\u003ctd\u003e2,000+ programs; 30+ approvals\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgriculture\u003c\/td\u003e\n\u003ctd\u003e~$16B market; $313M FY2025 revenue\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI protein design\u003c\/td\u003e\n\u003ctd\u003eEarly adoption, low share\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57235093487881,"sku":"twst-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/twst-bcg-matrix.webp?v=1785734380","url":"https:\/\/dcfanalyst.com\/products\/twst-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}